Genmab — Maj 2020
-
Og en tredje https://www.youtube.com/watch?v=y_AreleW-5A
-
Nu taler han i den første video om mulig kombination af de bispecifikke med andre immunterapier. Så var det jeg tænkte på, om ikke Novartis ville være en optimal partner. De har i forvejen Ofa, ofa er cd20, som slår B-celler ihjel. Og i kombi med epco? Bare en tanke.
-
Goder tanker Bulder.
-
-
Here is a Twitter answer I got regarding Amivantamab: CNS activity still needs further evaluation as many patients have brain mets.
-
@Sukkeralf you will get your LBA at EHA https://twitter.com/mbeksac56/status/1266700377522606080
-
Tror ikke vi allerede får dose-expansion (48mg) data på EHA. Updated dose-escalation data and RP2D will be presented. https://library.ehaweb.org/eha/2020/eha25th/293707/martin.hutchings.subcutaneous.epcoritamab.28gen3013.cd3xcd2029.in.patients.with.html?f=listing=0*browseby=8*sortby=1*search=epcoritamab
-
@GB jeg mener det er derfor de tester Amivantamab sammen med Lazertinib, som kan klare brain mets https://clinicaltrials.gov/ct2/show/NCT04077463
-
-
Tak peter12
-
Saad Usmani, MD, outlines the Phase 1 study investigating teclistamab in relapsed/refractory multiple myeloma https://obroncology.com/video-center/?category=all&subcategory=all&watch=NDg0NTEz
-
-
-
-
Usmani again https://www.youtube.com/watch?v=9MXX1-EP0i4
-
-
Det bemærkede jeg også i videoen.
-
Men ok. Det er jo Janssen som står for forsøget. https://www.ashclinicalnews.org/online-exclusives/early-data-teclistamab-shows-deep-responses-myeloma/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind